Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The Alzheimer's Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer's disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation.
Característiques principals
The ADDF created the Cohorts for Alzheimer’s Prevention Action (CAPA) Consortium to strengthen the evidence for potential preventative treatments. This program will fund specific analyses across a minimum of 5 longitudinal cohorts to examine the association of actionable interventions with the risk of cognitive aging, Alzheimer’s disease, related dementias, or biomarkers related to brain aging and neurodegeneration.
Lloc de presentació
El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
Marta López: mlopez4@imim.es Ext.: 1576
Carol Barnwell: cbarnwell@imim.es Ext.: 1670
Convocatòria (URL)
Convocatòria:
http://alzdiscovery.org/assets/content/static/RFP_for_CAPA_Cohort_Consortium_10_09_14.pdf
Dotació
$ 100,000
AVÍS IMPORTANT
All letters of intent and applications must be submitted electronically at www.alzdiscovery.org
NOTE: the website application instructions are currently tailored to our existing funding programs in drug discovery and development. Application instructions tailored to the CAPA consortium will be added to the website soon.
Submission of a Letter of Intent (LOI) is required by November 22, 2014
The deadline date for full applications is March 5, 2015.

Arxius

Arxiu
Request for Proposals